Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Aug 25;353(8):782-92.
doi: 10.1056/NEJMoa041773.

Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy

Daisuke Watanabe  1 , Kiyoshi Suzuma, Shigeyuki Matsui, Masafumi Kurimoto, Junichi Kiryu, Mihori Kita, Izumi Suzuma, Hirokazu Ohashi, Tomonari Ojima, Tomoaki Murakami, Toshihiro Kobayashi, Seiji Masuda, Masaya Nagao, Nagahisa Yoshimura, Hitoshi Takagi
Affiliations
Free article

Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy

Daisuke Watanabe et al. N Engl J Med. .
Free article

Abstract

Background: Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established.

Methods: We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo.

Results: The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients without diabetes (464.0 vs. 36.5 mIU per milliliter, P<0.001). The median VEGF level in patients with retinopathy was also significantly higher than that in patients without diabetes (345.0 vs. 3.9 pg per milliliter, P<0.001). Multivariate logistic-regression analyses indicated that erythropoietin and VEGF were independently associated with proliferative diabetic retinopathy and that erythropoietin was more strongly associated with the presence of proliferative diabetic retinopathy than was VEGF. Erythropoietin and VEGF gene-expression levels are up-regulated in the murine ischemic retina, and the blockade of erythropoietin inhibits retinal neovascularization in vivo and endothelial-cell proliferation in the vitreous of patients with diabetic retinopathy in vitro.

Conclusions: Our data suggest that erythropoietin is a potent ischemia-induced angiogenic factor that acts independently of VEGF during retinal angiogenesis in proliferative diabetic retinopathy.

PubMed Disclaimer

Comment in

  • Angiogenic pathways in diabetic retinopathy.
    Aiello LP. Aiello LP. N Engl J Med. 2005 Aug 25;353(8):839-41. doi: 10.1056/NEJMe058142. N Engl J Med. 2005. PMID: 16120866 No abstract available.
  • Erythropoietin as a retinal angiogenic factor.
    Manzoni P, Maestri A, Gomirato G, Takagi H, Watanabe D, Matsui S. Manzoni P, et al. N Engl J Med. 2005 Nov 17;353(20):2190-1; author reply 2190-1. doi: 10.1056/NEJM200511173532015. N Engl J Med. 2005. PMID: 16291990 No abstract available.

Publication types

MeSH terms